Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Chew

Showing results (131-140 of 214) with videos related to

Pageof 22
Sort By:
Scientific Reports|March 20, 2026
Association of long COVID with health-related quality-of-life outcomesMalini M Gandhi, Carlee Moser, Judith S Currier, et al.
Annals of Internal Medicine|February 21, 2023
Symptom and Viral Rebound in Untreated SARS-CoV-2 InfectionRinki Deo, Manish C Choudhary, Carlee Moser, et al.
Clinical Pharmacology and Therapeutics|July 7, 2022
Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS-CoV-2 InfectionRachel A Bender Ignacio, David A Wohl, Rosalin Arends, et al.
Medrxiv : the Preprint Server for Health Sciences|August 19, 2022
Viral and Symptom Rebound in Untreated COVID-19 InfectionRinki Deo, Manish C Choudhary, Carlee Moser, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2023
Statistical Challenges when Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical TrialsCarlee B Moser, Kara W Chew, Mark J Giganti, et al.
The Journal of Infectious Diseases|October 14, 2024
Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled TrialKara W Chew, Brooke McGinley, Carlee Moser, et al.
Eclinicalmedicine|September 10, 2024
Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trialTeresa H Evering, Carlee Moser, Nikolaus Jilg, et al.
Science Immunology|March 27, 2021
A tumor-specific mechanism of T<sub>reg</sub> enrichment mediated by the integrin αvβ8Robert I Seed, Kenji Kobayashi, Saburo Ito, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 17, 2024
SARS-CoV-2 Plasma Antibody and Nucleocapsid Antigen Status Predict Outcomes in Outpatients With COVID-19Nikolaus Jilg, Mark J Giganti, Kara W Chew, et al.
Plos Pathogens|April 18, 2024
Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibodyTin Phan, Carolin Zitzmann, Kara W Chew, et al.
Pageof 22

Showing results (131-140 of 214) with videos related to

Sort By:
Pageof 22
Scientific Reports|March 20, 2026
Association of long COVID with health-related quality-of-life outcomesMalini M Gandhi, Carlee Moser, Judith S Currier, et al.
Annals of Internal Medicine|February 21, 2023
Symptom and Viral Rebound in Untreated SARS-CoV-2 InfectionRinki Deo, Manish C Choudhary, Carlee Moser, et al.
Clinical Pharmacology and Therapeutics|July 7, 2022
Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS-CoV-2 InfectionRachel A Bender Ignacio, David A Wohl, Rosalin Arends, et al.
Medrxiv : the Preprint Server for Health Sciences|August 19, 2022
Viral and Symptom Rebound in Untreated COVID-19 InfectionRinki Deo, Manish C Choudhary, Carlee Moser, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2023
Statistical Challenges when Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical TrialsCarlee B Moser, Kara W Chew, Mark J Giganti, et al.
The Journal of Infectious Diseases|October 14, 2024
Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled TrialKara W Chew, Brooke McGinley, Carlee Moser, et al.
Eclinicalmedicine|September 10, 2024
Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trialTeresa H Evering, Carlee Moser, Nikolaus Jilg, et al.
Science Immunology|March 27, 2021
A tumor-specific mechanism of T<sub>reg</sub> enrichment mediated by the integrin αvβ8Robert I Seed, Kenji Kobayashi, Saburo Ito, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 17, 2024
SARS-CoV-2 Plasma Antibody and Nucleocapsid Antigen Status Predict Outcomes in Outpatients With COVID-19Nikolaus Jilg, Mark J Giganti, Kara W Chew, et al.
Plos Pathogens|April 18, 2024
Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibodyTin Phan, Carolin Zitzmann, Kara W Chew, et al.
Pageof 22